Sarepta Therapeutics (SRPT) Stock Statistics & Valuation Metrics

Sarepta Therapeutics has a market cap or net worth of $1.72B. The enterprise value is $12.00B.

Sarepta Therapeutics has 98,277,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sarepta Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.06%.

The current PE Ratio of Sarepta Therapeutics is 49.14. Sarepta Therapeutics’s PEG ratio is -0.29.

In the last 12 months, Sarepta Therapeutics had revenue of 1.90B and earned 235.24M in profits. Earnings per share was 2.34.

In the last 12 months, operating cash flow was -547.15M and capital expenditures -140.40M, giving a free cash flow of -687.55M billion.

Sarepta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Sarepta Therapeutics upcoming earnings date is Jul 30, 2025, After Close (Confirmed).

Sarepta Therapeutics as a current ratio of 4.20, with Debt / Equity ratio of 420.15%

In the past 12 months, Sarepta Therapeutics has paid 25.54M in taxes.

Sarepta Therapeutics EV to EBITDA ratio is 35.43, with an EV/FCF ratio of -34.43.

Sarepta Therapeutics has $522.76M in cash and marketable securities with $1.34B in debt, giving a net cash position of $820.99M billion.

Gross margin is 85.00%, with operating margin of 11.47%, and net profit margin of 12.37%.

The average price target for Sarepta Therapeutics is $42.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy